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Many important aspects of human retroviral infections cannot be fully evaluated using only in vitro
systems or unmodiﬁed animal models. An alternative approach involves the use of humanized mice,
which consist of immunodeﬁcient mice that have been transplanted with human cells and/or tissues.
Certain humanized mouse models can support robust infection with human retroviruses including
different strains of human immunodeﬁciency virus (HIV) and human T cell leukemia virus (HTLV). These
models have provided wide-ranging insights into retroviral biology, including detailed information on
primary infection, in vivo replication and pathogenesis, latent/persistent reservoir formation, and novel
therapeutic interventions. Here we describe the humanized mouse models that are most commonly
utilized to study retroviral infections, and outline some of the important discoveries that these models
have produced during several decades of intensive research.
& 2015 Elsevier Inc. All rights reserved.
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Introduction
Infectious agents exact a devastating daily toll of morbidity and
mortality worldwide (WHO, 2014). This not only creates millions of
personal tragedies each year, but also deeply affects wider commu-
nities as the economic and social impact of infectious disease is
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borne by society as a whole. Fortunately, the application of basic
and translational scientiﬁc research coupled with careful clinical
studies has produced a range of vaccines and therapeutic agents
that can prevent, treat, or cure previously common human diseases.
These successes are built on a foundation of studying the causative
organism in relevant biological systems that are suitable for
investigating its replication and pathogenesis, and which in turn
may be used to evaluate new therapies.
Researchers in the biological sciences are continually striving to
develop improved in vitro approaches that mimic natural hosts
more completely. However, in vitro systems represent isolated
situations that cannot fully emulate the complexity of an in vivo
environment. In some cases unmodiﬁed animals have proven to be
suitable models for studying human pathogens, but this method
carries the limitations that the microorganism must be able to
replicate efﬁciently and ideally should cause disease within the
animal host species, and that interaction with animal rather than
human cells and tissues are being studied.
A powerful complementary approach to in vitro or unmodiﬁed
animal studies is the use of humanized mice. These are mice that
have either been engineered to express human genes or (as will
primarily be discussed in this review) immunodeﬁcient mice that
have been reconstituted with human cells and/or tissues. One
particular area of research in which humanized mice have proven
useful is in the ﬁeld of retrovirology. Retroviruses are important
human pathogens, and humanized mice have provided important
insights into many aspects of retrovirus biology, including trans-
mission, in vivo replication and pathogenesis, latent/persistent
reservoir formation, and evaluation of novel therapeutic interven-
tions. The purpose of this review is to provide a background on
retroviral studies in humanized mice, explain the main types of
humanized mouse models currently in use, and provide some
examples of the many important areas of retrovirus research that
have beneﬁted from the use of humanized mice.
Exogenous retroviruses in humans
Currently, four exogenous retroviruses have been identiﬁed
that are endemic in certain human populations: human immuno-
deﬁciency virus type 1 and 2 (HIV-1 and HIV-2), and human T cell
lymphotropic virus type 1 and 2 (HTLV-1 and HTLV-2). Additional
retroviruses including HTLV-3, HTLV-4, and human foamy virus
(Mahieux and Gessain, 2011; Meiering and Linial, 2001) are
occasionally found in rare individuals, but this is generally the
result of infrequent zoonotic transmission of related simian viruses.
Consequently, the majority of humanized mouse studies of retro-
viruses have focused on HIV, and to a much lesser extent on HTLV.
HIV is a lentivirus which infects and depletes CD4þ T cells,
leading to the development of acquired immune deﬁciency syn-
drome (AIDS), which typically manifests approximately 10 years after
primary infection with the virus (Barre-Sinoussi et al., 1983; Gallo
et al., 1983). HIV originated in nonhuman primates in West Africa.
The most common strains of HIV type 1 (HIV-1) are derived from a
related simian immunodeﬁciency virus (SIV) SIVCPZ present in
chimpanzees (Pan troglodytes troglodytes), whereas HIV-2 is derived
from SIVSMM in sooty mangabeys (Cercocebus atys) (Hirsch et al.,
1989; Keele et al., 2006; Sharp and Hahn, 2011). Over the past
century, more than 10 different strains of either HIV-1 or HIV-2 have
jumped into humans through independent zoonotic transmission
events. The most prevalent of these (HIV-1, group M) was trans-
mitted into humans approximately 100 years ago and is responsible
for well over 90% of global HIV infections (Worobey et al., 2008). HIV-
2 also causes AIDS but is associated with lower viral loads and
reduced person-to-person transmission rates, and has not spread
substantially from West Africa (Reeves and Doms, 2002; Sharp and
Hahn, 2011). Overall, approximately 35 million people are currently
infected with HIV and a similar number have already died of AIDS
(UNAIDS, 2013).
HTLV is likely to also have originated in non-human primates,
which carry related simian T cell lymphotropic viruses (Proietti
et al., 2005). However HTLVs have potentially been present in
humans for thousands of generations (Weiss, 1996). HTLV-1 infects
around 10–20 million people worldwide and is endemic in regions
of Japan, Caribbean islands, South America, and equatorial Africa.
The majority of HTLV-1-infected individuals remain asymptomatic,
but approximately 5% of carriers go on to develop adult T cell
leukemia (ATL) or HTLV-associated myelopathy/tropical spastic para-
paresis (HAM/TSP) (Proietti et al., 2005). More rarely, other condi-
tions including infective dermatitis and HTLV-associated uveitis are
also caused by HTLV-1 (Proietti et al., 2005). HTLV-2 has not been
causatively linked to any disease.
These retroviral infections of humans, particularly the devas-
tating HIV epidemic, provided a strong impetus for the develop-
ment of animal models that would allow their study in relevant
in vivo systems.
Animal models of retroviral infection
Many aspects of retroviral infection cannot be adequately inves-
tigated in infected humans. This is in part because detailed studies of
in vivo retroviral replication and pathogenesis necessitate that infec-
tions be performed under controlled conditions with pre-deﬁned
viral variants. Invasive sampling of tissues at speciﬁc post-infection
timepoints is also often required. Furthermore, the risks associated
with experimental treatments are often too great to perform early
efﬁcacy testing in infected patients, and instead can only be reason-
ably performed in relevant animal models.
Early virus challenge experiments showed that HIV cannot
infect unmodiﬁed small animals (Morrow et al., 1987). Conse-
quently, most in vivo modeling of HIV has focused on alternative
approaches. HIV-1 can infect chimpanzees but ethical concerns
and their endangered status, coupled with other issues including
infrequent and slow development of disease (Keele et al., 2009)
now effectively preclude the use of chimpanzees in laboratory HIV
research. Certain SIVs can infect and cause AIDS-like disease in
non-human primates such as rhesus (Macaca mulatta), cynomol-
gous (Macaca fascicularis), or pigtailed (Macaca nemestrina) maca-
ques. These models have therefore been used to investigate
replication and pathogenesis of a virus that is closely related to
HIV, with many of the ﬁndings subsequently translated to HIV
(Gardner and Luciw, 2008; Hatziioannou and Evans, 2012; Letvin
et al., 1985). A variety of modiﬁed chimeric SIV/HIV viruses termed
simian-human immunodeﬁciency viruses (SHIVs) have also been
created, which can replicate in nonhuman primates (Hatziioannou
and Evans, 2012). This allows, for example, antiretroviral drugs or
vaccine candidates that are directed towards HIV rather than SIV
proteins to be evaluated in simian models. Non-human primate
models have limitations in that they are expensive and individual
studies are usually restricted to relatively small numbers of
animals. The required use of an SIV or SHIV strain of virus also
means that some aspects of the interaction between wild-type HIV
and human cells or tissues cannot be adequately studied in these
models.
Mice have been used to model human disease for many years.
Studies with mouse models beneﬁt from their small size, relatively
short generation time, and the fact they share many features of
physiology and immune function with humans. However mice
cannot be infected by HIV, and no murine lentivirus that might
serve as a natural model for HIV infection of mice has been found.
Transgenic mice that have increased susceptibility to HIV infection
through the engineered expression of human HIV entry receptors
(CD4 and CCR5) have produced useful information, but are limited
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by the fact that murine cells harbor multiple post-entry blocks
that severely limit HIV replication (Bieniasz and Cullen, 2000;
Browning et al., 1997). Transgenic expression of the HIV genome
or individual HIV gene products in mice has also provided insights
into aspects of HIV disease progression (Hanna et al., 1998; Leonard
et al., 1988; Sun et al., 2008) but are similarly limited by restricted
HIV expression and lack of HIV replication in mouse cells.
In summary, while these models have proved extremely useful
in the study of HIV, small animal models that allow complementary
information to be gained using wild-type HIV infecting human cells
in an in vivo experimental setting are still important. While rabbit,
non-human primate, and rat models of HTLV-1 infection also exist,
they similarly have limitations that make complementary studies
with humanized mice valuable (reviewed in Dodon et al. (2012)).
For these reasons humanized mouse models have been extensively
utilized to study many aspects of pathogenesis and treatment of
retroviruses which infect humans.
A brief overview of immunodeﬁcient mice
Mice with an intact immune system will rapidly clear trans-
planted human cells through a vigorous innate and adaptive immune
response. It was thus only with the identiﬁcation and selection of
immunodeﬁcient mouse strains that maintenance of transplanted
human cells in the mouse became possible. The history of humanized
mouse development is thus closely linked to the sequential devel-
opment of increasingly immunodeﬁcient mouse strains that can
serve as recipients for xenografts with human cells or tissues. Some
signiﬁcant developments in the history of humanized mouse models
and a few of the many examples of their use in retrovirus research
are provided (Fig. 1). It is worth noting that the nomenclature
surrounding immunodeﬁcient mouse strains and humanized mouse
models is rather tangled. This is partly due to the fact that speciﬁc
genes related to immune function have in some cases been disrupted
in different ways, leading to different genotypes of mice showing
similar phenotypes. Crossing of previously separate immunodeﬁcient
mouse strains along with further targeted disruption of immune-
related genes has also increased the diversity of available immuno-
deﬁcient strains. Finally, the common names for the humanized
mouse models themselves are not necessarily applied universally,
and might refer to either identical or broadly similar procedures
performed in any one of several recipient mouse strains (Shultz et al.,
2012, 2007).
Nude mice were ﬁrst described in the 1960s (Flanagan, 1966).
These mice carry a mutation in the gene encoding the forkhead
box protein N1 (Foxn1nu) which leads to abnormal hair growth and
an athymic phenotype due to defects in the development of thymic
stroma (Nehls et al., 1994). Nude mice thus do not produce mature
CD4þ and CD8þ T cells and have severely impaired B cell function
due to a lack of T cell help. They proved useful for transplant of
HIV Latency formation in BLT mice 
(Marsden et al., 2012, Denton et al., 2012)
Infection of SCID-hu
mice with HTLV-1
(Feueret al., 1993)
Protection against HIV mediated by Ab-
based vectored immunoprophylaxis
(Balazs et al., 2012)
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(Lapidotet al., 1992)
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gamma chain-(Il2rg) 
deficient mice
(Cao et al., 1995 & 
DiSanto et al., 1995)
NOD-scid mice
(Shultz et al., 1995)
NOD/Schi-scid Il2rg-/- (NOG) mice 
& immune system development 
following human CD34+ cell 
transplant 
(Ito et al., 2002)
Near-complete immune 
system development in 
newborn BALB/cRag2-/-
Il2rg-/ - (BRG) mice 
injected   intrahepatically
with CD34+ cells 
(Traggiai et al., 2004)
NOD/LtSz-scid Il2rg -/-
(NSG) mice & their 
engraftment with 
CD34+ cells to 
develop a human 
immune system 
(Ishikawa et al., 2005)
(Shultz et al., 2005)
Bone marrow -liver-
thymus (BLT) mice 
(Melkuset al., 2006, 
Lanet al., 2006)
Infection of the SCID- hu
mouse with HIV-1 
(Namikawaet al., 1988)
First evaluation of an 
antiretroviral drug (AZT) in 
SCID-hu mouse 
(McCune et al., 1990)
In vivo depletion of CD4+ 
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following HIV infection 
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(Aldrovandiet al., 1993, 
Bonyhadi et al., 1993)
NOD-Rag1-/- mice
(Shultz et al., 2000)
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(Brooks et al., 2001)
HIV Latency in Hu-HSC mice 
(Choudhary et al., 2012)
HTLV-1 adult 
leukemia model 
developed by 
intra-bone 
marrow injection 
of stem cells in 
NOG mice 
(Tezukaet al. 
2014)
SCID-hu model 
(McCune et al., 1988)
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(Mosier et al., 1988)
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thymic
development in 
Rag2-/-IL2rg -/- mice 
(Villaudy et al. 2011)
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by “noncytopathic” HIV 
isolates in hu-PBL-SCID model
(Mosier et al., 1993)
HTLV-1 infection of human 
PBMC-NOG mice
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Advances in Humanized mouse models
Example uses of humanized mouse models in retrovirology
Infection of hu-PBL-SCID
mice with HIV
(Mosier et al., 1991)
Fig. 1. Timeline describing some signiﬁcant advances in humanized mouse models and examples of their application in retrovirology research.
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human cells, particularly in the study of cancer (Fu et al., 1991).
However, nude mice retain substantial immune function, making
them inadequate to serve as the basis for a robust humanized
mouse model that would allow effective engraftment with primary
human cells or tissues. This became possible with the description of
severe combined immunodeﬁcient (scid) CB17 mice (Bosma et al.,
1983). These mice have a mutation that developed spontaneously in
the protein kinase, DNA activated, catalytic polypeptide gene
(Prkdcscid), which encodes a DNA repair enzyme that is required
for T cell and B cell receptor gene rearrangement. Consequently
SCID mice have no functional T or B cells, and can be used in long-
term transplant of primary human cells and tissues. Limitations of
SCID mice included the fact that in older animals some production
of B and T cells is observed (i.e. “leakiness”). The deﬁciencies in DNA
repair in SCID mice also leads to them being more sensitive to
radiation and some chemotherapy drugs than other mouse strains.
Furthermore, CB17-scid mice retain innate immune responses
including NK cell function. This problem could be partially amelio-
rated by using a non-obese diabetic (NOD) background strain,
which resulted in NOD-scid mice with lower levels of innate
immunity including reduced complement activity and NK cell
function (Shultz et al., 1995).
T-cell and B-cell receptor rearrangement also requires the
action of recombination-activating gene 1 (Rag 1) and Rag 2 gene
products. Targeted disruption of these genes individually has also
led to the production of mouse strains that produce no T or B cells
and are more radiation resistant than scid strains (Mombaerts
et al., 1992; Shinkai et al., 1992). Similarly to NOD-scid mice, these
Rag knockout mice strains lack adaptive immune responses but
still harbor signiﬁcant innate immune responses that hinder long-
term, systemic reconstitution with human cells.
It was only when the targeted disruption of the coding
sequence for the interleukin (IL)-2 receptor common gamma chain
(Il2rg, also referred to as γc) was achieved by several different
laboratories that substantial systemic reconstitution of immuno-
deﬁcient mice with human cells became possible (Cao et al., 1995;
DiSanto et al., 1995; Jacobs et al., 1999; Ohbo et al., 1996).
The common gamma chain is shared by the receptors for IL-2,
IL-4, IL-7, IL-9, IL-15, and IL-21, and its disruption profoundly
affects innate and adaptive immune function, and importantly
results in a complete lack of NK cells, primarily due to the
absence of IL-15 signaling (Kennedy et al., 2000; Ranson
et al., 2003).
The most common mouse strains currently in use as platforms for
humanized mouse experiments are the NOD.Cg-PrkdcscidIl2rgtm1Wjl
(NSG), the NODShi.Cg-PrkdcscidIl2rgtm1Sug (NOG) and various strains
similar to C;129S4-Rag2tm1FlvIl2rgTm1Flv (BRG) as described in more
detail elsewhere (Ito et al., 2012; Shultz et al., 2012). NSG mice do not
express IL2rg and thus their cells cannot bind the relevant cytokines,
while in NOG mice the common gamma chain receptor has a deleted
cytoplasmic domain, which can bind cytokines but does not signal.
BRG mice have strain-dependent disruptions in IL2rg, which are
either non-expressed or incapable of intracellular signaling (Shultz
et al., 2012).
Researchers are continuously striving to generate new mouse
strains with an improved capacity to reconstitute with human
cells. For example, one limitation of some humanized mouse models
is the development of graft-versus-host-disease (GVHD), where the
implanted cells mount an immune response against those of the host.
This can be reduced through disruption of important murine immune-
related genes including β2 microglobulin, resulting in a lack of cell
surface major histocompatibility complex (MHC) class I expression
Liver
Thymus
Human
thy/ liv
implant
Mouse
Kidney
Hu- HSC
(hematopoietic stem cells)
General Procedure:
• Condition with irradiation.
• Inject  HSC via intrahepatic, intracardiac, or facial vein for newborn 
mice. Inject via intrafemoral or intravenous route for adult mice.
Result: Generates near-complete human immune system. Cells are 
educated in mouse rather than human thymus and so are not HLA
restricted. Can produce some primary immune responses.
SCID-hu
(thymus liver)
General Procedure:
• Implant human fetal thymus and liver fragments under 
renal capsule.
Result:Good model for thymopoiesis. Reconstitutes primarily 
with thymocytesand naïve T cells. Human cells largely 
constrained to implant, with limited numbers present in 
spleen and peripheral organs. Little or no primary immune 
response.
Hu-PBL-SCID
(peripheral blood leukocytes/peripheral blood mononuclear cells)
General Procedure:
• Inject PBL through intraperitoneal, intravenous, or intrasplenic route.
Result: Engraftment is particularly efficient with human T cells. Human cells are 
present in peritoneal cavity, peripheral blood and spleen. Transplanted cells are 
activated and generate graft versus host disease over time.Specific primary immune 
responses are difficult to generate. Some recall immune responses are observed.
Peripheral blood 
leukocytes
Hematopoietic stem cells
BLT
(Bone marrow-liver-thymus)
General Procedure:
• Implant human fetal thymus and liver fragments under renal capsule.
• Condition with irradiation or busulfan treatment.
• Inject HSC (from same donor as thy/liv tissue) intravenously.
Result: Multilineage hematopoietic reconstitution with human cells 
including T cells, B cells, monocyte/macrophages, and NK cells. Human 
cells are present in multiple tissues including the thy/liv implant, spleen, 
peripheral blood, lung, liver, gut, and vaginal mucosa. Greatly improved 
mucosal immunity over Hu-HSC. Can generate some primary immune 
responses.
thy/liv implant
thy/liv implant
+
Hematopoietic stem cells
Fig. 2. Overview of the major humanized mouse models used in retrovirus research.
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(Christianson et al., 1997), or MHC class II (King et al., 2009). Other
advances in immunodeﬁcient mice have included the transgenic
expression of human HLA molecules (Danner et al., 2011) or expres-
sion of human cytokines including macrophage colony-stimulating
factor, granulocyte–macrophage colony-stimulating factor, and IL-3
(Rathinam et al., 2011; Willinger et al., 2011), resulting in improved
reconstitution or enhanced functionality of particular hematopoietic
lineages of human cells in the mouse. Efforts to reduce rejection of
implanted human cells have included the generation of CD47-kockout
mice. The interaction between signal regulatory protein (SIRP)-α and
CD47 is required to suppress phagocytosis of cells by macrophages.
Murine macrophages do not recognize human CD47, and thus can
phagocytose transplanted human HSCs. However, it has been shown
that in CD47-knockout BRGmice this requirement is negated, allowing
the development of high levels of human multilineage hematopoiesis
and reduced GVHD following transplant of human fetal thymus and
HSCs (Lavender et al., 2013). Additional techniques for reducing the
rejection of transplanted human cells in disease models involving
transplant of fetal thymus and allogenic HSCs have also been devel-
oped. These include the depletion of endogenous thymocytes present
within the transplanted fetal tissue using an anti-human CD2 mono-
clonal antibody and cryopreserving then thawing the tissue prior to
transplantation (Kalscheuer et al., 2012).
Common humanized mouse models used in retroviral research
In parallel with the development of immunodeﬁcient mouse
models, methods for engrafting these animals with primary human
cells also improved. Four basic models for humanization of immu-
nodeﬁcient mice have been developed (Fig. 2), although these have
each been further adapted in various ways to optimize them for
particular applications. Early pioneering studies in mouse humani-
zation involved the injection of human peripheral blood mono-
nuclear cells into the intraperitoneal cavity of CB17-scid mice
(Mosier et al., 1988). In the original description of this hu-PBL-
SCID model, the cells persisted for over six months and could
produce some speciﬁc immune responses in vivo (Mosier et al.,
1988). Importantly, the hu-PBL-SCID model could also be infected
with HIV, with virus recoverable from the spleen, peripheral blood,
peritoneal cavity, and lymph nodes for up to 16 weeks after
infection (Mosier et al., 1991). The hu-PBL-SCID model beneﬁts
from its relative simplicity, strong engraftment with T cells, and the
fact that it can be used for infection soon after the human cells are
injected (Rizza et al., 1996). However, this model is somewhat
limited by the development of GVHD, which generally is evident
within three to four weeks after transplant of human cells. Levels of
reconstitution in the CB17-scidmouse were also relatively poor. This
was improved 5–10-fold by the use of NOD-scid mice (Hesselton
et al., 1995), and further enhanced with the use of NSG recipient
mice, which also allowed substantial engraftment following intra-
venous injection rather than only through an intraperitoneal route
(King et al., 2008; Kumar et al., 2008).
A further breakthrough approach in modeling human hemato-
poiesis in immunodeﬁcient mice was the development of the
SCID-hu model, also referred to as the “SCID-hu (Thy/Liv)” model
(McCune et al., 1988). This model was created by implanting
fragments of human fetal liver as a source of hematopoietic stem
cells (HSCs) along with human fetal thymus tissue under the
kidney capsule of SCID mice, resulting in the formation of a new
conjoint organ that is structurally and functionally similar to a
human thymus. In this implant, human T cells undergo normal
thymopoiesis through a CD4þCD8þ (double-positive) phase before
differentiating into single-positive naïve CD4þ or CD8þ T cells.
Human cells can be maintained in this model for over 1 year. The
SCID-hu model proved invaluable for studying T cell development
(Namikawa et al., 1990), and could readily be infected with HIV by
direct injection of virus into the implant, thereby providing a robust
in vivo model for studying HIV replication (Namikawa et al., 1988).
Early SCID-hu studies involved co-implantation of human lymph
node tissues, which allowed intravenous infection and could be
used to model virus interaction with human secondary lymphoid
organs (Kaneshima et al., 1991). However the majority of reported
SCID-hu studies involve only implantation of the thymus and liver
tissue. Implants can also be placed under the capsules of both
kidneys, resulting in greater numbers of human T cells in the
peripheral blood, spleen, and lymph nodes (Kollmann et al., 1994).
However, even with this modiﬁcation, SCID-hu mice have poor
peripheral lymphoid compartment reconstitution with human cells
and produce little or no primary cellular or humoral immune
responses. Additional limitations of the SCID-hu model include
the need for surgery during implantation and the requirement for
human fetal tissues.
A third model for humanizing mice has variously been termed
human-hematopoietic stem cell (hu-HSC), human-SCID reconsti-
tuting cell-SCID (hu-SRC-SCID), or sometimes human immune
system (HIS) mice (Lapidot et al., 1992). In this model multi-
lineage human hematopoiesis can be generated in various strains
of immunodeﬁcient mice by subjecting them to sublethal irradia-
tion to clear space in the bone marrow then injecting human
hematopoietic stem cells (HSCs). Experiments were originally
conducted using CB17-scid mice but improved reconstitution can
be achieved with NSG or NOG mice (Lepus et al., 2009; Manz,
2007). A wide range of different parameters have been evaluated
for this model, all of which can affect the levels and quality of
human cell engraftment. These include the individual mouse
strain used, the age of the animal, the speciﬁc radiation source
or chemotherapy agent used for ablation, the source of human
HSCs, and the route of HSC administration to the mice (Brehm
et al., 2010; Hayakawa et al., 2009; Ito et al., 2012; Lepus et al.,
2009). HSCs for this model are typically sourced from fetal liver or
cord blood, but can also be obtained from bone marrow, or human
peripheral blood from individuals who have received granulocyte
colony-stimulating factor to mobilize CD34þ cells (Ito et al., 2012).
Reconstitution is particularly effective in newborn mice, which are
already undergoing vigorous hemato-lymphoid expansion (Brehm
et al., 2010). Primary immune responses are generated in this
model, but are limited in some respects. For example antibody
responses are often weak and largely restricted to IgM due to
inefﬁcient class switching (Akkina, 2013; Ishikawa et al., 2005;
Manz, 2007; Traggiai et al., 2004; Watanabe et al., 2007) pre-
sumably due to a lack of helper T cell function. It has also been
noted that an autoantibody-like response can be generated in hu-
HSC mice, suggesting that in some cases antibody responses can
be skewed in this mouse model (Chang et al., 2012).
Finally, a combination of the hu-HSC and SCID-hu models termed
the bone marrow–liver–thymus (BLT) model has been developed. This
model involves the implantation of adult immunodeﬁcient mice with
fetal thymus and liver tissue followed by sublethal irradiation then
injection of HSCs (Lan et al., 2006; Melkus et al., 2006). This provides
the opportunity for T cells to be educated on human thymic stroma
and results in reconstitution with all lineages of immune cells
including excellent T cell reconstitution. Human immune cells are
present in multiple organs including the peripheral blood, thy/liv
implant, lymph nodes, spleen, gut, lungs, bone marrow, brain and liver
(Melkus et al., 2006; Shimizu et al., 2010). This model has also been
modiﬁed in various ways, including the use of NSG recipient mice
rather than the originally described NOD/SCID strain. Other alterations
have included the use of busulfan rather than irradiation to induce
myelosuppression, surgical implantation under the renal capsule of
both kidneys to increase T cell numbers, and the dissagregation of liver
tissue followed by reassembly using a matrigel scaffold prior to
implantation (Shimizu et al., 2010). This last modiﬁcation allows HSCs
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to be extracted from the liver tissue, transduced with a gene of
interest, and then transplanted along with thymus tissue, resulting in a
higher frequency of transgene-expressing cells. The BLT model has
proven useful in studying some primary immune responses to HIV,
and produces particularly efﬁcient mucosal reconstitutionwith human
cells compared with other available models. Limitations of this model
include the requirement for surgery, the need for fetal tissue, and an
approximately 12 week waiting period between transplantation and
full reconstitution.
HIV studies in humanized mouse models
Soon after the development of each major humanized mouse
model they were also tested and found to be susceptible to
infection with HIV. These models have therefore been invaluable
in both improving our understanding of HIV biology and as
systems for evaluation of novel anti-HIV therapeutics. The exam-
ples outlined below are by no means exhaustive, but are instead
intended to illustrate some important uses of both the older
hu-PBL-SCID and SCID-hu models and the more recently devel-
oped and versatile hu-HSC and BLT mice. Historically, studies of
HIV in humanized mice have primarily focused on HIV-1 because
this virus is responsible for the vast majority of global HIV
infections (Sharp and Hahn, 2011).
Pathogenesis and depletion of HIV target cells
When the hu-PBL-SCID and SCID-hu models were developed in
the late 1980s, the HIV coreceptors (primarily CXCR4 and CCR5)
had not yet been discovered and the relationship between a virus
clone's ability to replicate effectively or induce syncytia formation
in vitro and its capacity to replicate and cause disease in vivo was
not clear. Humanized mice provided an in vivo environment to
address these issues.
Indeed, soon after the hu-PBL-SCID model was shown to be
capable of supporting HIV replication (Mosier et al., 1991) it was
demonstrated that so called “noncytopathic” (R5-tropic) HIV could
induce extensive CD4þ T cell depletion in this model, illustrating
that in vitro cytopathicity does not predict the ability of a viral
strain to deplete CD4þ cells in vivo (Mosier et al., 1993).
HIV infection of the SCID-hu mouse also results in depletion of
HIV target cells, with the initial loss of CD4þCD8þ (double
positive) thymocytes followed by selective loss of CD4þ (single-
positive) cells, resulting in an inversion of normal CD4/CD8 ratios
(Aldrovandi et al., 1993; Bonyhadi et al., 1993). The length of time
before severe depletion of HIV target cells is evident varies accord-
ing to viral strain, but typically occurs at 3–9 weeks post-infection.
This hypocellularity is accompanied by further pathological changes
in the implant which are visible histologically, including thymic
involution and loss of cortical–medullary junctions (Jamieson et al.,
1996). The presence of additional lineages of cells in the SCID-hu
mouse also allowed the evaluation of indirect effects of HIV on cells
that are not generally considered hosts for the virus. For example,
HIV infection is well known to affect multiple different hematopoi-
etic lineages in addition to CD4þ T cells, resulting in anemia,
thrombocytopenia, granulocytopenia, and myelodysplastic altera-
tions of the bone marrow (Calenda and Chermann, 1992). One
potential contributing factor to this was identiﬁed following HIV
infection of SCID-hu mice, where virus infection was found to
disrupt ex vivo myeloid and erythroid colony-forming activity of
progenitor cells through indirect mechanisms (without HIV infec-
tion of CD34þ cells), potentially through perturbation of cytokine
levels (Jenkins et al., 1998; Koka et al., 2003, 1998, 1999). More
recently studies using BLT mice also demonstrated direct HIV
infection of human intermediate hematopoietic progenitor cells
(Nixon et al., 2013), thus a direct killing mechanism may also
contribute to the hematopoietic abnormalities seen in untreated
HIV disease.
In some respects HIV infection of the original hu-PBL-SCID and
SCID-hu models emulate the early stages of HIV infection in
humans, with exponential virus replication accompanied by pro-
found CD4 depletion within weeks of infection in the absence of a
speciﬁc antiviral immune response. In contrast, some of the newer
hu-HSC and BLT models provide an environment that is more
typical of later stages of HIV infection in humans, with speciﬁc
primary cellular and (albeit limited) humoral immune responses
present and slower CD4 declines. For example, studies of HIV
infection of a hu-HSC model based on BRG mice showed that these
mice can be infected with both X4 and R5 HIV variants, and that
plasma viremia can be sustained for over 4 months and in some
cases longer that 1 year (Berges et al., 2006, 2008; Zhang et al.,
2007). Hu-HSC based on NOG mice was similarly found to be
susceptible to X4 and R5 viruses and produced an antibody
response to HIV Env and Gag epitopes, with no signiﬁcant CD4
depletion evident following infection with the R5 virus for over 40
days (Watanabe et al., 2007). This difference between models is
further supported by the fact that little selective viral evolution is
observed during HIV infection of SCID-hu mice (Jamieson et al.,
1995), whereas BLT mouse infection is associated with the devel-
opment of HIV-speciﬁc CD8þ T cell immune responses and rapid
viral evolution, predominantly in CD8þ T cell epitopes (Dudek
et al., 2012). Rates of viral evolution of the HIV env gene in hu-HSC
mouse infections lasting up to 44 weeks were also found to be
similar to those in infected humans over similar periods of time
(Ince et al., 2010), indicating that these models can be used to study
HIV evolution and adaptation in a complex host environment.
HIV can also infect cells in the brain (primarily parenchymal
microglia and perivascular microglia/macrophages) and cause
both encephalitis and HIV associated dementia (Anthony and
Bell, 2008). Humanized mice have the potential to emulate various
aspects of HIV neruopathogenesis, but many questions remain
(Honeycutt et al., 2014). In particular, the application of newer
models such as the BLT mouse could improve our understanding of
the mechanisms underlying virus-induced central nervous system
damage and whether the brain contains a reservoir of HIV that can
persist despite suppression of HIV replication by antiretroviral
drugs (Honeycutt et al., 2014).
Humanized mouse models are still utilized to answer funda-
mental questions about the ability of HIV to replicate and deplete
target cells in a relevant in vivo system. For example, BLT mice have
recently been employed to evaluate the in vivo replication capacity
of viruses isolated from untreated HIVþ patients who have unde-
tectable viral loads (elite controllers/suppressors), demonstrating
that these viruses are replication-competent and capable of inducing
CD4þ T cell depletion in vivo. This study shows that the viral strains
in these individuals are not obviously attenuated and that elite
suppressors can control infection with apparently fully pathogenic
viruses (Salgado et al., 2014).
Function of different HIV gene products and other viral genetic
elements
HIV has been intensively studied for over three decades and we
arguably knowmore about this virus than any other human pathogen.
However, the vast body of accumulated research, including extensive
biochemical and in vitro analysis of HIV proteins and non-coding
sequences is often difﬁcult to connect directly to HIV replication and
pathogenesis in vivo. Humanized mouse models have proven useful as
one measure for evaluating the biological relevance of in vitro ﬁndings
in a more physiologically relevant environment.
M.D. Marsden, J.A. Zack / Virology 479-480 (2015) 297–309302
An illustrative example of the use of humanized mouse models
to better understand the determinants of HIV pathogenesis is the
case of the HIV Nef protein. HIV negative effect factor (Nef) was
originally found in some cases to reduce HIV expression in culture
(Ahmad and Venkatesan, 1988; Luciw et al., 1987). However there
was also evidence that Nef is required for efﬁcient replication in
primary cells and therefore the actual role of Nef in HIV replication
and pathogenesis was unclear (Kirchhoff and Hunsmann, 1992).
Using the SCID-hu model it was demonstrated that nef was
required for in vivo replication and pathogenicity (CD4 depletion),
even in cases where nef-defective mutants replicated similarly to
wild-type virus levels in vitro (Jamieson et al., 1994). Similar studies
were conducted using the hu-PBL-SCID model, which showed that nef
deletion in several virus strains delays increases in plasma viremia and
slows but does not prevent CD4þ T cell depletion, reinforcing the
importance of Nef for in vivo HIV replication (Gulizia et al., 1997). More
detailed analysis of Nef function in vivo was then performed using a
panel of nef-deﬁcient viruses, which identiﬁed key regions of the viral
protein that are important for replication and CD4 depletion, including
the myristolation site and the region encoding amino acids 41–49 of
Nef. Conversely, two PXXP SH3 binding domains were not found to be
important for in vivo replication, suggesting that some functions of Nef
identiﬁed by in vitro testing may not inﬂuence in vivo pathogeneses
(Aldrovandi et al., 1998). This was further characterized using addi-
tional mutant viruses in the SCID-hu mouse to show that it is
the capacity of Nef to downregulate CD4 that correlates with Nef-
mediated enhancement of pathogenicity, rather than other Nef func-
tions such as MHC class I downregulation, (Pxx)4-associated enhance-
ment of infectivity, or HCK binding (Stoddart et al., 2003). Later studies
in the BLT mouse model similarly showed that nef-deleted virus
results in an infection characterized by lower viral loads and reduced
CD4 depletion. However the extensive tissue repopulation with
human cells in BLT mice made it possible to demonstrate reduced
depletion of CD4þ cells by the nef-deleted virus in a wider range of
tissues including peripheral blood, lymph nodes, spleen, Thy/Liv
implant, bone marrow, lung, and liver (Zou et al., 2012). In summary,
the use of various humanized mouse models has clariﬁed our under-
standing of the in vivo function of Nef, and helped bridge the gap in
knowledge between suggestive and in some cases contradictory
in vitro experimental studies and observations of HIV in infected
patients, where natural infection with nef-defective viruses has been
associated with slower disease progression (Deacon et al., 1995).
Studies utilizing additional HIV-1 accessory gene mutants
tested in the SCID-hu mouse demonstrated that these viruses
differed profoundly in their infectivity, replicative capacity, and
ability to deplete CD4þ cells (Aldrovandi and Zack, 1996). In these
assays nef-minus virus proved the most attenuated, with vpu and
vif mutant viruses also showing signiﬁcantly reduced infectivity
and modestly reduced pathogenicity. In contrast vpr-deleted virus
had little or no effect on any of these parameters (Aldrovandi and
Zack, 1996). Analysis of mutant HIV viruses in humanized mice has
not been restricted to only protein-coding sequences. HIV has an
array of non-coding elements within its genome that are evolu-
tionarily conserved but whose contribution to HIV replication and
pathogenesis is difﬁcult to resolve using only in vitro assays. For
example, the modest in vivo reduction in HIV replication and
pathogenesis observed in the SCID-hu mouse infected with a virus
encoding a disrupted HIV “central DNA ﬂap” helped resolve
differing reports concerning the relative importance of this ele-
ment based on in vitro observations of mutant virus replication
(Marsden and Zack, 2007).
Efﬁcacy of antiretroviral drugs
Evidence that humanized mice would become a powerful tool in
the preclinical evaluation of antiretroviral drugs came when the
nucleoside analog reverse transcriptase inhibitor 30-azido-30deoxy-
thymidine (AZT) was found to be effective at suppressing virus
replication in SCID-hu mice (McCune et al., 1990b). Follow-up studies
with 20,30-dideoxinosine (ddI) yielded similar results, and the doses
used (after the application of allometric scaling to account for higher
drug metabolism in the mouse) were similar to those found effective
in patients (McCune et al., 1990a). Additional studies using different
classes of antiretroviral drugs have further validated the use of the
SCID-hu model in the comparative evaluation of antiretroviral drug
efﬁcacy (Stoddart et al., 2007, 2012).
In the early days after combination antiretroviral therapy (ART)
became available it was not clear whether inhibition of virus
replication would be sufﬁcient to fully restore immune compe-
tency, or conversely whether virus-induced damage to primary
and secondary lymphoid organs would prove irreversible even in
further virus replication was inhibited by ART. The SCID-hu model
was employed to address this issue, and evaluate how suppression
of virus replication with antiretroviral therapy affects T cell
generation. Treatment of infected SCID-hu mice with combination
ART resulted in renewed thymopoiesis with a normal distribution
of T-cell receptor variable gene families, demonstrating that HIV-
induced damage to thymic tissue did not prevent generation of
new T cells if virus replication was prevented by antiretroviral
drugs (Kitchen et al., 2000; Withers-Ward et al., 1997).
The in vivo consequences that accompany the development of
resistance to antiretroviral drugs are also difﬁcult to predict from
exclusively in vitro testing. Humanized mouse models have also
proved useful in this regard, including the use of SCID-hu mice to
demonstrate that protease inhibitor resistant viruses have impaired
replication in vivo (Stoddart et al., 2001).
ART effectively inhibits HIV replication in hu-HSC and BLT mouse
models (Choudhary et al., 2009; Denton et al., 2012; Halper-
Stromberg et al., 2014; Marsden et al., 2012) and results in viral
rebound if ART is stopped or drug resistant viruses evolve in vivo
(Choudhary et al., 2012; Denton et al., 2012). Recent studies in BLT
mice have further showed that the inclusion of an anti-HIV immu-
notoxin along with antiretroviral therapy diminished productively
infected cells not eliminated by the antiretroviral drugs alone
(Denton et al., 2014). Use of these newer models will therefore not
only be useful in determining the in vivo efﬁcacy of new antiretroviral
drugs, but also in the investigation of antiretroviral drug resistance
development and exploring the reservoirs of virus that persist
during ART.
Humanized mice are also suitable for evaluation of naturally
occurring agents with putative antiviral activity. For example the
interferon-inducible cholesterol-25-hydroxylase converts cholesterol
into the soluble antiviral factor 25-hydroxycholesterol (25HC), and it
has recently been shown that 25HC can inhibit the growth of
numerous enveloped viruses (Blanc et al., 2011; Liu et al., 2013).
The in vivo functionality of 25HC against HIV was demonstrated with
the administration of 25HC to hu-HSC humanized mice prior to HIV
infection, which resulted in reduced viral loads, fewer HIV-infected
cells, and protection of CD4þ cells from depletion (Liu et al., 2013).
Transmission and prophylaxis
The early virologic and immunologic events accompanying HIV
transmission are difﬁcult to study in infected people for many
reasons. Individuals are generally unaware of their infected status
until symptoms appear and much of the early virus replication
occurs in tissues that are not easily accessible using clinical sampling.
Clinical trials directed towards preventing transmission of virus are
also expensive, logistically challenging, and require a large number of
participants. Humanized mice have therefore been applied to the
study of HIV transmission and evaluation of methods for preventing it.
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Several early studies using the hu-PBL-SCID model showed that
passive immunization with neutralizing monoclonal antibodies
could protect against infection with HIV (Parren et al., 1995; Safrit
et al., 1993), and protection could also be achieved in this model
evenwhen Abwas administered several hours after challenge with
primary HIV isolates (Gauduin et al., 1997). More recently, inhibition
of HIV transmission with new generations of broadly-neutralizing
antibodies that recognize and neutralize diverse HIV strains have
represented a particularly promising area of research that is very
amenable to study using humanized mice. For example, a hu-HSC
model was used to show that a mixture of 3 broadly-neutralizing
antibodies can prevent HIV transmission (as assessed by the presence
of detectable plasma viremia) in some cases when added beginning
4 days post-infection (Halper-Stromberg et al., 2014).
Studies of mucosal HIV transmission and the use of topical
microbicides to inhibit transmission via this route have also beneﬁted
greatly from humanized mouse studies. Because hu-PBL-SCID and
SCID-hu models do not produce signiﬁcant human immune cells in
the vaginal mucosa, early studies were performed by infecting PBL
with HIV and then performing vaginal administration, resulting in the
infection of animals challenged in this way (Di Fabio et al., 2001). The
advent of Hu-HSC models allowed the study of mucosal transmission
of HIV through vaginal and rectal routes in a more physiologic setting
(Berges et al., 2008), and with the extensive mucosal reconstitution
with human immune cells achieved in the BLT mouse model the
systematic testing of HIV transmission and intervention studies
became possible (Denton et al., 2008; Stoddart et al., 2011). These
studies of mucosal transmission in BLT mice have yielded a variety of
clinically relevant observations regarding the biology of HIV transmis-
sion across intact mucosal surfaces and the efﬁcacy of different
intervention strategies. For example, the BLT mouse has been used
to demonstrate the efﬁcacy of antiretroviral pre-exposure prophylaxis
in preventing vaginal (Denton et al., 2008) and rectal (Denton et al.,
2010) HIV transmission. Inhibition of vaginal HIV transmission by the
topical administration of an antiretroviral drug (Denton et al., 2011),
and the ability of human breast milk to reduce oral HIV transmission
have also been demonstrated in this model (Wahl et al., 2012). In
summary, these humanized mouse models have proved to be useful
in the evaluation of mucosal HIV infection, and provide relevant
systems for evaluation and optimization of future therapeutics
intended to prevent the transmission of HIV.
Gene therapy/engineered immunity
Gene therapy approaches represent attractive opportunities to
prevent or treat HIV infection (reviewed in Marsden and Zack
(2013)) and humanized mice have been invaluable in the assess-
ment of these efforts. The new generations of humanized mice are
particularly conducive to stem cell gene therapies, since the
protocols for manufacture of these mice already require the
enrichment of HSCs. If the HSC are genetically modiﬁed before
transplant, then progeny cells that differentiate in the mouse will
also harbor the modiﬁed genome. Indeed, humanized mice were
used to ﬁrst demonstrate lentiviral vector-mediated gene delivery
into human long-term repopulating HSCs (Miyoshi et al., 1999).
This strategy has been used to evaluate various stem cell gene
therapy approaches for inhibiting HIV.
Approximately 1% of Caucasians are homozygous for a 32 base pair
deletion in the gene for CCR5, a chemokine receptor that also
functions as the HIV coreceptor (CCR5-Δ32). This results in a
truncated CCR5 protein that is not expressed on the cell surface. These
individuals are highly resistant to HIV infection but otherwise healthy.
Furthermore, the bone marrow transplant from a CCR5-Δ32 homo-
zygous donor to an HIV positive individual undergoing aggressive
treatment for acute myeloid leukemia (the “Berlin Patient”) represents
the only reported case of an apparent HIV cure (Hutter et al., 2009)
(reviewed in Marsden and Zack (2013)). This has provided a strong
impetus for the use of corrective gene therapy to emulate a CCR5-
deﬁcient protective phenotype in autologous cells fromHIVþ patients.
Promising research in this area has included the development of an
RNAi approach to knock-down CCR5 RNA via lentiviral vector delivery
(Qin et al., 2003). shRNA knockdownwas then shown to be effective at
inhibiting R5 HIV infection ex vivo after differentiation of the resistant
cells in the BLT mouse (Shimizu et al., 2010). Direct disruption of the
CCR5 gene in HSC using zinc-ﬁnger nucleases has also been achieved,
resulting in control of R5 HIV infection in hu-HSC mice (Holt et al.,
2010). CD4þ T cells can also be disrupted for CCR5 or CXCR4 (an
alternative HIV coreceptor) using zinc-ﬁnger nucleases, and then
transplanted into immunodeﬁcient mice to validate function (Perez
et al., 2008; Wilen et al., 2011; Yuan et al., 2012).
It is likely that similarly to what is seen with antiretroviral
drugs, for genetic therapies against HIV to be truly efﬁcacious they
must also involve a combination approach targeting multiple viral
or cellular targets. This would allow enhanced virus suppression
while making the evolution of viral variants that are resistant to
the gene therapy less likely. Therefore more complex approaches
involving multiple therapeutic genes are also being explored. For
example a Hu-PBL model was used to show that a lentiviral vector
encoding a multiplexed construct expressing seven anti-HIV shRNAs
(one targeting CCR5 and six targeting the HIV genome) could
suppress in vivo HIV replication and protect from CD4þ T cell
depletion when HIV infected cells were transduced with a lentiviral
vector before transfer into NSG mice (Choi et al., 2014). Similarly a
combination shRNA approach targeting CCR5 (as described above) as
well as the R region of the HIV long terminal repeat, protected cells
from HIV-induced depletion by R5- and X4-tropic HIV in BLT mice
(Ringpis et al., 2012).
Additional gene therapy approaches that involve modulating
anti-viral immune responses have also been evaluated in
humanized mice. These include the generation of HIV-speciﬁc
cytotoxic T lymphocytes via transgenic expression of a T cell receptor
delivered to hematopoietic progenitor cells (Kitchen et al., 2012),
and the use of broadly-neutralizing antibodies encoded by
adeno-associated virus vectors, which are expressed following intra-
muscular injection and result in secretion of antibody that protects
against intravenous or vaginal challenge with HIV (Balazs et al., 2012,
2014).
In summary, a wide array of novel gene therapy approaches
have been tested in humanized mice. Importantly, while the
studies above are directed towards HIV, the broad approaches
are also applicable to other infectious agents (Balazs et al., 2013;
Deal et al., 2014). Therefore the importance of these humanized
mouse studies goes beyond HIV research and therapeutics.
Additional therapeutics
Humanized mouse models for HIV have also been crucial in the
evaluation of new delivery systems or therapeutic approaches
targeting HIV. Both Hu-PBL mice and Hu-HSC mice were used to
show that a CD7-speciﬁc single chain antibody conjugated to
oligo-9-arginine peptide (scFvCD7-9R) could be used to deliver
siRNA speciﬁcally to T cells in vivo. Delivery of anti-CCR5 siRNA or
other antiviral siRNAs in this manner resulted in suppression of
HIV viremia in the mice (Kumar et al., 2008). A dendrimer-based
nanoparticle-mediated delivery of combinatorial dicer substrate
short-interfering RNAs (dsiRNAs) targeting HIV or cellular tran-
scripts has also been tested in humanized mice. These novel
particles suppressed HIV viral loads and prevented CD4þ T cell
depletion after intravenous administration to Hu-HSC mice (Zhou
et al., 2011). Similar inhibition of HIV replication was reported
using an RNA aptamer designed to bind to HIV envelope gp120
protein and neutralize virus, either with or without a conjugated
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siRNA targeting the tat/rev common exon of HIV (Neff et al., 2011).
Humanized mouse models have also been used to evaluate novel
preparations of antiviral agents, including long acting nanoformu-
lated ART (Dash et al., 2012). These diverse studies show the
versatility of humanized mouse models in evaluating a wide range
of novel therapeutics targeting HIV.
Viral persistence and latency
Combination ART is capable of inhibiting HIV replication and
often results in undetectable plasma viral loads in treated indivi-
duals. However, replication-competent HIV is still present in rare
latently-infected cells, which harbor integrated, non-expressing
viral genomes that can be induced to produce infectious virus if
stimulated (Chun et al., 1997b) (reviewed in Marsden and Zack
(2010, 2013)). Based on ex vivo viral outgrowth assays, approxi-
mately 1 million of these latently-infected cells are present in each
infected patient at a frequency of around 1 per million resting
CD4þ T cells (Chun et al., 1997a), although this is likely a minimal
estimate (Ho et al., 2013). These cells decay very slowly in vivo
with a half-life of approximately 44 months, and are capable of
persisting for decades (Finzi et al., 1999). Therefore if the patient
stops taking ART then the presence of this reservoir allows virus to
rapidly re-emerge (Chun et al., 1999). Consequently, while other
reservoirs of persistent HIV might also exist, latently-infected cells
are considered to be one of the main barriers to an HIV cure.
Humanized mice have been particularly useful in the study of
latent HIV. HIV can productively infect activated cells but not
resting cells (Stevenson et al., 1990; Zack et al., 1990). It is therefore
believed that one means by which HIV latency forms in vivo is
when an activated cell becomes infected by HIV but transitions to
a resting CD4þ T cell before it can be killed by the virus or
immune response. This may happen during memory formation,
when an activated CD4þ T cell becomes a resting memory CD4þ
T cell. However a similar reduction in cellular activation also
occurs during thymopoiesis when a CD4þCD8þ double-positive
cell transitions to a resting naïve CD4þ single-positive T cell.
Indeed, it was found that when CD4þCD8þ (double positive) cells
are infected by HIV in the SCID-hu mouse and then transition to
CD4þ (single positive) cells, this can be associated with establish-
ment of latency (Brooks et al., 2001). The high frequency of
infected cells in this model coupled with the rapid differentiation
of T cells results in a relatively large percentage (in some cases
45%) of the CD4þ T cells in HIV infected implants harboring
latent virus. This model was subsequently used to evaluate various
aspects of latent HIV infection. It was found that the non-tumor
inducing phorbol ester prostratin (Korin et al., 2002) and inter-
leukin 7 (Scripture-Adams et al., 2002) could each activate expression
of latent HIV ex vivo. Furthermore these recently activated latently-
infected cells could be depleted with the addition of an anti-HIV
envelope immunotoxin, which can bind to and kill cells expressing
HIV envelope proteins on their surface (Brooks et al., 2003b). Without
stimulation, latently infected cells showed no obvious distinguishing
features that might be used to differentiate them from their uninfected
counterparts (Brooks and Zack, 2002). These latently-infected cells
were also found also to be most responsive to stimulants that function
via protein kinase C or nuclear factor of activated T cells (NF-AT)
(Brooks et al., 2003a), and HIV transcription was initiated very rapidly
upon stimulation of the host cell, with signiﬁcant increases in
intracellular HIV mRNA evident within 2 h of stimulation (Arlen
et al., 2006). Latently-infected cells from the SCID-hu model were also
used to evaluate novel methods for inducing expression of latent HIV.
For example, lipid nanoparticles loaded with the protein kinase C
activating compound bryostatin 2 were used to activate HIV expres-
sion from latently-infected CD4þ SCID-hu thymocytes ex vivo,
validating a novel delivery method for HIV latency activating com-
pounds (Kovochich et al., 2011).
HIV latency has also been shown to form following infection of
BLT (Denton et al., 2012; Marsden et al., 2012) and hu-HSC
(Choudhary et al., 2012) mice. In these studies the mice were
infected and then treated with antiretroviral therapy to suppress
plasma viral loads and emulate the situation in infected patients. A
modiﬁcation of the SCID-hu mouse model where thy/liv implants
are inserted under the kidney capsule of NSG mice (as opposed to
the standard NOD/SCID) was recently shown to generate substan-
tial systemic reconstitution with human T cells, but not other
immune lineages including monocyte/macrophages, B cells, or
dendritic cells. This model, termed a T cell only mouse (TOM) also
permits the formation of HIV latency (Honeycutt et al., 2013).
These models are now being utilized to test methods for eliminat-
ing persistent HIV reservoirs. For example, broadly neutralizing
anti-HIV envelope antibodies were used to suppress viral loads in
HIV-infected hu-HSC mice and then followed with administration
of a combination of three different HIV latency activating reagents
(Halper-Stromberg et al., 2014). This resulted in a lack of viral
rebound in over half of the treated mice once antibody levels
waned, suggesting that the combination of neutralizing antibodies
and viral inducers had reduced the levels of underlying latent or
persistent virus that would otherwise contribute to viral rebound
(Halper-Stromberg et al., 2014; Marsden and Zack, 2014). These
models should continue to serve as useful frameworks for experi-
ments designed to investigate HIV latency and persistence during
therapy, and in the evaluation of new agents intended to eliminate
the latent reservoir of HIV.
HTLV
HTLV has not been studied extensively in humanized mice, but
some humanized mouse models for investigating HTLV-1 infection
have been developed, which broadly parallel those used for the
study of HIV. These models have provided complementary informa-
tion to data obtained from other animal models of HTLV, which do
not adequately model all aspects of viral pathogenesis, particularly
the complex mechanisms underlying the process of leukemogenesis
(Dodon et al., 2012). Early humanized mouse studies with HTLV
focused on the use of SCID mice as recipients in a hu-PBL-SCID
model, where PBL from asymptomatic HTLV-1 positive individuals or
patients diagnosed with ATL or HAM/TSP were introduced to the
mice (Feuer et al., 1993). This resulted in a persistent infection with
HTLV characterized by a proliferative advantage for the HTLV-
infected cells, and the development of lymphoblastic lymphomas
in animals injected with PBL from two ATL patients (Feuer et al.,
1993). Experiments involving either the injection of HTLVþ cell
lines, or alternatively ATL patient cells obtained from either periph-
eral blood or lymph node coupled with daily injection of interleukin
2, yielded comparable results (Imada et al., 1995; Kondo et al., 1993).
As was identiﬁed with other humanized mouse experiments based
on CB17-scid mice, the presence of mouse NK cells in these animals
was problematic and prevented engraftment of HTLV-1 in vitro
transformed cell lines (Stewart et al., 1996). This could be partially
improved by approaches including the pre-treatment of mice with
anti-murine IL-2 receptor antibody to deplete NK cells, whole-body
irradiation, or treatment of mice with anti-asialo GM1 antibody,
which transiently inhibits in vivo NK cell activity (Feuer et al., 1995;
Kondo et al., 1993). The use of NOD/SCID mice further improved
engraftment efﬁciency, particularly when coupled with sublethal
whole-body irradiation (Liu et al., 2002). This approach led to rapid
tumor development within 2–3 weeks of engraftment in all of the
tested animals. The neoplastic cells were widely distributed, invad-
ing and displacing organs including the spleen, liver, abdominal
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wall musculature, kidney, pancreas, and intestine. All of these
tumors contained HTLV-1 tat/rex sequences and human β-globin
sequences, indicating that they were derived from the engrafted
transformed cell line (Liu et al., 2002).
A hu-PBL-SCID model system based on NOG mice has also been
successfully used to study HTLV-1 infection by co-inoculating mice
with human lymphocytes and the HTLV-1 producing cell line MT-2,
resulting in the presence of proviral DNA in both CD4þ and CD8þ T
cells (Miyazato et al., 2006). This model was also suitable for testing
inhibition of infection with antiretroviral drugs. The reverse transcrip-
tase inhibitors AZT and tenofovir prevented primary infection when
administered soon after infection, but did not affect proviral loads if
administered 1 week post-infection suggesting that after the early
stages of infection, clonal proliferation of infected cells was primarily
responsible for increases in proviral DNA (Miyazato et al., 2006). More
recently, a humanized mouse model based on bone marrow injection
of human CD133þ stem cells into NOG mice has been used to study
HTLV. Upon infection of this model, an increase in CD4þ T cells was
observed in the periphery, which was eventually dominated by a
limited number of CD25þ cells. Importantly, this model also pro-
duced HTLV-speciﬁc immune responses allowing the study of tumor
formation in the face of an adaptive human immune response (Tezuka
et al., 2014). This should pave the way for future studies of HTLV
infection in humanized mice that focus on the complex interplay
between virus proliferation and the host immune response.
Summary
Humanized mice have provided numerous insights into retro-
viral replication and pathogenesis and represent versatile systems
for testing novel therapeutics targeting retroviral infections. As
these models are further optimized to more completely replicate
the human immune system they will only become more useful in
future retroviral studies, with broad applications in the evaluation
of vaccine candidates, gene therapy approaches, and small mole-
cule therapeutics intended to achieve the difﬁcult task of either
preventing initial infection or permanently eliminating these
deadly viruses from infected individuals.
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